Table 1.
Demographics and baseline characteristics of patients
| Characteristics | Total (n = 74) | Platinum sensitive (n = 11) | Platinum resistant (n = 63) |
|---|---|---|---|
| Age, years | |||
| Median (range) | 57.0 (32–76) | 55.0 (40–72) | 58.0 (32–76) |
| Primary cancer (%) | |||
| Epithelial ovarian carcinoma | 62 (83.8) | 11 (100.0) | 51 (81.0) |
| Peritoneal carcinoma | 12 (16.2) | 0 (0.0) | 12 (19.0) |
| Tumour histology (%) | |||
| Serous | 49 (66.2) | 6 (54.5) | 43 (68.3) |
| Endometrioid | 8 (10.8) | 3 (27.3) | 5 (7.9) |
| Clear cell | 8 (10.8) | 1 (9.1) | 7 (11.1) |
| Mucinous | 1 (1.4) | 0 (0.0) | 1 (1.6) |
| Other | 8 (10.8) | 1 (9.1) | 7 (11.1) |
| Initial FIGO stage (%) | |||
| I | 7 (9.5) | 1 (9.1) | 6 (9.5) |
| II | 1 (1.4) | 1 (9.1) | 0 (0.0) |
| III | 50 (67.6) | 6 (54.5) | 44 (69.8) |
| IV | 16 (21.6) | 3 (27.3) | 13 (20.6) |
| Previous chemotherapy (%) | |||
| 1 regimen | 23 (31.1) | 11 (100.0) | 12 (19.0) |
| 2 regimen | 50 (67.6) | 0 (0.0) | 50 (79.4) |
| 3 regimen | 1 (1.4) | 0 (0.0) | 1 (1.6) |
| Previous chemotherapy with antracycline (%) | |||
| Yes | 3 (4.1) | 0 (0.0) | 3 (4.8) |
| No | 71 (95.9) | 11 (100.0) | 60 (95.2) |
| Platinum-free interval (days) | |||
| Median (range) | 263 (28–2792) | 315 (216–441) | 235 (28–2792) |
| CA-125 at baseline (U/ml) | |||
| Median (range) | 243.6 (5.8–7809.8) | 192.1 (22.2–808.0) | 261.0 (5.8–7809.8) |
FIGO, Federation Internationale de Gynecologie et d'Obstetrique.